News Column

Findings on Immunotherapy Reported by Researchers at Department of Neuroscience (Developing therapeutic antibodies for neurodegenerative disease)

August 13, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Biotechnology. According to news reporting originating in San Francisco, California, by NewsRx journalists, research stated, "The central nervous system has been considered off-limits to antibody therapeutics. However, recent advances in preclinical and clinical drug development suggest that antibodies can cross the blood-brain barrier in limited quantities and act centrally to mediate their effects."

The news reporters obtained a quote from the research from the Department of Neuroscience, "In particular, immunotherapy for Alzheimer's disease has shown that targeting beta amyloid with antibodies can reduce pathology in both mouse models and the human brain, with strong evidence supporting a central mechanism of action. These findings have fueled substantial efforts to raise antibodies against other central nervous system targets, particularly neurodegenerative targets, such as tau, beta-secretase, and alpha-synuclein. Nevertheless, it is also apparent that antibody penetration across the blood-brain barrier is limited, with an estimated 0.1-0.2 % of circulating antibodies found in brain at steady-state concentrations. Thus, technologies designed to improve antibody uptake in brain are receiving increased attention and are likely going to represent the future of antibody therapy for neurologic diseases, if proven safe and effective. Herein we review briefly the progress and limitations of traditional antibody drug development for neurodegenerative diseases, with a focus on passive immunotherapy."

According to the news reporters, the research concluded: "We also take a more in-depth look at new technologies for improved delivery of antibodies to the brain."

For more information on this research see: Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics, 2013;10(3):459-72. (Elsevier - www.elsevier.com; Neurotherapeutics - www.elsevier.com/wps/product/cws_home/711525)

Our news correspondents report that additional information may be obtained by contacting Y.J. Yu, Neurodegeneration Labs, Dept. of Neuroscience, Genentech, Inc, 1 DNA Way, South San Francisco, San Francisco, CA, United States (see also Biotechnology).

Keywords for this news article include: Antibodies, Biotechnology, California, Immunology, Therapeutics, San Francisco, United States, Immunotherapy, Blood Proteins, Immunoglobulins, Immunomodulation, Blood Brain Barrier, North and Central America, Neurodegenerative Diseases, Central Nervous System Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters